Overview
The Heart Failure Department, established in 2013, is among the pioneering heart failure specialties in China. In 2018, it expanded into a Heart Failure Center accredited by the China Cardiovascular Association, and in 2021, it was recognized as a Quality Control Model by the China Heart Failure Center Association. Our department is dedicated to advancing both basic and clinical diagnosis and treatment, with a focus on standardized medication and device treatments for heart failure.
Expert Team
Our department boasts a team of 2 chief physicians, 1 associate chief physician, 2 PhD tutors, and 6 attending physicians. Professor LIU Zhongmin, our academic leader, is renowned for his work in artificial heart development, heart and lung transplantation, and stem cell therapy for heart failure. He holds prestigious positions such as the inaugural chairperson of the Disaster Medicine Branch of the Chinese Medical Association, director of the World Association for Disaster and Emergency Medicine, and the chairperson of the Cardiovascular Surgeon Branch of the Chinese Medical Doctor Association. Professor HAN Wei, the department director, holds several significant roles in national and international cardiology organizations, such as the American College of Cardiology (FACC), the Heart Failure Group of the Cardiovascular Disease Branch of the Chinese Medical Association and the China Heart Failure Center.
Services
Our department specializes in a range of advanced therapies, including stem cell therapy, neural blockade therapy, and gene-based drug therapy. We have established standardized diagnosis, treatment, and follow-up processes for patients with complex and critical heart failure. By collaborating with secondary hospitals and community hospitals, we have built a comprehensive heart failure management closed-loop system, ensuring continuous and coordinated care for our patients.
Innovations & Achievements
Our department has undertaken over 40 national and provincial programs, including the National Program on Key Basic Research Project (“973” Program), High-tech R&D Program of China (“863” Program), and international cooperation programs from the Ministry of Science and Technology. Supported by the National Natural Science Foundation of China (NSFC), National Health Commission, and National Administration of Traditional Chinese Medicine, our research funding exceeds tens of millions. We have published over 100 articles in domestic and international journals, with more than 30 included in SCI, and a total impact factor exceeding 100.
Academic Performance
Our research has made significant contributions to the field, with notable discoveries and advancements in heart failure treatment. Professor Liu has received prestigious awards, including the second prize of the National Science and Technology Progress Award and the Science and Technology Progress Award from the Ho Leung Ho Lee Foundation. Our team continues to lead innovative research in heart failure, contributing to the global body of knowledge and improving patient outcomes.
Commitments
Our department is deeply committed to delivering exceptional care for heart failure patients, grounded in a practical approach that emphasizes scientific treatment, effectiveness, and empathy. We are steadfast in our mission to provide top-tier services, ensuring that our patients benefit from the best possible medical interventions and support throughout their healthcare journey.
